Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Multiple Ascending Oral Doses of Olorofim in Healthy Subjects
NCT02737371Phase 1Completed
- Sponsor
- F2G
- Start
- May 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olorofim in invasive aspergillosis (IA) (6 arms), sponsored by F2G. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 10 days. Started May 2016; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02737371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737371.